Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profilesfor RMC-4630 Combined with Cobimetinib and Early Evidence of Clinical Activity in RASmut Colorectal Cancers
Company Also Announces New Clinical Collaboration with
Related News
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
October 24, 2020 Early Dose-Escalation Data Demonstrate Proof of Mechanism and Support Ongoing Development of SY-5609 for Difficult-to-Treat Cancers On Track to Report...
Public Technologies 2020-10-24Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
PDF Version First and only chemoprotective therapy in clinical development that utilizes a biomarker strategy designed to protect patients with p53-mutated cancers from...
Public Technologies 2020-10-24Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan Revocan is designed to...
Public Technologies 2020-10-21Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory ...
TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2020-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has...
The Marshall News Messenger
2020-10-22
Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 ...
SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target...
Tyler Morning Telegraph
2020-10-22
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has...
PR Newswire 2020-10-23Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
PDF Version Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
Public Technologies 2020-10-22Related News
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel ...
Tyler Morning Telegraph
2020-10-24